Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reldesemtiv in ALS
NCT04944784Phase 3Terminated
- Sponsor
- Cytokinetics
- Start
- Aug 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 3 trial of reldesemtiv in amyotrophic lateral sclerosis (ALS), sponsored by Cytokinetics. Started Aug 2021; status: terminated.
02
Drugs
reldesemtiv
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04944784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04944784.